Cardium Therapeutics, Inc. (CXM) CSO Dr. Rubanyi Authors Generx Publication in Molecular Therapy
Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today highlighted the publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors," authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's chief scientific officer in the April issue of Molecular Therapy. The publication frameworks the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including information on designating appropriate clinical trial endpoints, selecting patients who are likely responders to therapeutic stimulation of collateral development, and potential genetic and molecular…